LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Actinium Pharmaceuticals Inc

Slēgts

1.81 8.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.62

Max

1.84

Galvenie mērījumi

By Trading Economics

Ienākumi

-9.3M

-16M

EPS

-0.51

Darbinieki

31

EBITDA

-9.3M

-17M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+255.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.2M

51M

Iepriekšējā atvēršanas cena

-6.57

Iepriekšējā slēgšanas cena

1.81

Actinium Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. jūn. 20:45 UTC

Peļņas

Broadcom 2Q Sales Climb on Booming AI Demand

2025. g. 5. jūn. 23:45 UTC

Tirgus saruna

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

2025. g. 5. jūn. 23:44 UTC

Tirgus saruna

Gold Edges Higher on Weak U.S. Data -- Market Talk

2025. g. 5. jūn. 23:30 UTC

Tirgus saruna

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

2025. g. 5. jūn. 21:32 UTC

Peļņas

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025. g. 5. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 5. jūn. 20:45 UTC

Peļņas

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025. g. 5. jūn. 20:24 UTC

Peļņas

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Rev $15B >AVGO

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Net $4.97B >AVGO

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Adj EPS $1.58 >AVGO

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom 2Q EPS $1.03 >AVGO

2025. g. 5. jūn. 20:15 UTC

Peļņas

Broadcom Sees 3Q Rev $15.8B >AVGO

2025. g. 5. jūn. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

2025. g. 5. jūn. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

2025. g. 5. jūn. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

2025. g. 5. jūn. 19:22 UTC

Tirgus saruna

Oil Futures Resume Upward Moves -- Market Talk

2025. g. 5. jūn. 19:00 UTC

Tirgus saruna

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025. g. 5. jūn. 18:32 UTC

Tirgus saruna

Gold Slips After Trump-Xi Call -- Market Talk

2025. g. 5. jūn. 18:26 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

2025. g. 5. jūn. 18:06 UTC

Tirgus saruna

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

2025. g. 5. jūn. 16:30 UTC

Iegādes, apvienošanās, pārņemšana

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

2025. g. 5. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 5. jūn. 16:18 UTC

Tirgus saruna

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

2025. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 5. jūn. 16:12 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 5. jūn. 16:12 UTC

Tirgus saruna

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

2025. g. 5. jūn. 16:03 UTC

Tirgus saruna

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

2025. g. 5. jūn. 15:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Actinium Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

255.03% augšup

Prognoze 12 mēnešiem

Vidējais 6 USD  255.03%

Augstākais 9 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Actinium Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.